COMMUNIQUÉS West-GlobeNewswire

Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
09/05/2025
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) , a biotechnology company historically focused on the development of a differentiated approach to [...]
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
08/05/2025
Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with [...]
Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates
08/05/2025
Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while [...]
Treace Medical Concepts Reports First Quarter 2025 Financial Results
08/05/2025
PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Cytek Biosciences Reports First Quarter 2025 Financial Results
08/05/2025
FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first [...]
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance
08/05/2025
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to [...]
Fulcrum Therapeutics to Participate in Upcoming May Conferences
08/05/2025
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Senseonics Holdings, Inc. Reports First Quarter Financial Results
08/05/2025
Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist ™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with [...]
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
08/05/2025
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for [...]
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter [...]
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in [...]
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date CALM-CAH Phase 3 Study of Atumelnant for the Treatment of [...]
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
08/05/2025
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, [...]
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
08/05/2025
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of [...]
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
08/05/2025
Six posters presented at the American Association for Cancer Research (AACR) annual meeting Appointment of Dr. Sabeen Mekan as Senior Vice President, Clinical Development Reported $321.6 million in cash resources as of [...]
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
08/05/2025
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data [...]
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15
08/05/2025
DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic [...]
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
08/05/2025
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and [...]
TerrAscend Reports First Quarter 2025 Financial Results
08/05/2025
Net Revenue of $71 million Gross Profit Margin of 51.8%, up 160 basis points from 50.2% in the fourth quarter of 2024 Net Cash provided by operations of $8.0 million and Free Cash Flow ¹ of $5.5 million 11 th [...]

Pages